logo

INBS

Intelligent Bio·NASDAQ
--
--(--)
--
--(--)
0.54 / 10
Underperform

Fundamental assessment yields a 0.54/10 score, Underperform. Asset‑MV and Profit‑MV are modestly positive, but Revenue‑MV, Cash‑MV, ROA and profit margins are deeply negative. Overall financial health appears weak and selective.

Fundamental(0.54)SentimentTechnical

Analysis Checks(2/10)

Revenue-MV
Value-2.44
Score0/3
Weight21.28%
1M Return-4.18%
ROA (%)
Value-96.28
Score0/3
Weight23.51%
1M Return-6.58%
Net cash flow from operating activities / Operating revenue (%)
Value-250.10
Score0/3
Weight23.56%
1M Return-6.63%
Profit-MV
Value0.66
Score2/3
Weight-20.10%
1M Return3.09%
Annualized net profit margin on total assets (%)
Value-96.28
Score0/3
Weight23.51%
1M Return-6.58%
EBIT / Total operating revenue (%)
Value-275.12
Score1/3
Weight3.96%
1M Return-0.83%
Asset-MV
Value-0.55
Score3/3
Weight-30.53%
1M Return4.62%
Net profit / Total operating revenue (%)
Value-274.07
Score0/3
Weight23.99%
1M Return-6.68%
Cash-MV
Value0.02
Score1/3
Weight19.05%
1M Return-4.16%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight11.77%
1M Return-2.39%
Is INBS undervalued or overvalued?
  • INBS scores 0.54/10 on fundamentals and holds a Premium valuation at present. Backed by its -82.61% ROE, -257.72% net margin, -0.49 P/E ratio, 0.51 P/B ratio, and -37.36% earnings growth, these metrics solidify its Underperform investment rating.